Cue Biopharma (CUE) Price & Analysis

Compare

629 Followers

CUE Stock Chart & Stats

$0.34

-$0.18(-11.25%)

At close: Jan 08 4:00 PM EST

$0.34

-$0.18(-11.25%)

Day’s Range― - ―

52-Week Range$0.47 - $1.75

Previous CloseN/A

Volume91.78K

Average Volume (3M)238.59K

Market Cap

$21.99M

Enterprise Value$45.27M

Total Cash (Recent Filing)$18.67M

Total Debt (Recent Filing)$6.17M

Price to Earnings (P/E)―

Beta1.50

Next Earnings

Mar 24, 2026

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding91,237,740

10 Day Avg. Volume365,762

30 Day Avg. Volume238,588

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)3.51

Price to Sales (P/S)6.61

P/FCF Ratio-1.69

Enterprise Value/Market Cap2.06

Enterprise Value/Revenue6.38

Enterprise Value/Gross Profit6.45

Enterprise Value/Ebitda-1.28

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Partnership And CollaborationsWith a potential partnership upcoming for CUE-501 and a cash position of $22.5MM, Cue remains an attractive investment opportunity with upside potential if a partnership materializes.

Product DevelopmentCue regained the global rights for CUE-401 from Ono and expects to submit an IND, indicating progress in their product development pipeline.

Bears Say

Clinical Development ChallengesThe presence of confounding variables and lack of a partner may hinder the clinical development progress of CUE-101.

Program DeprioritizationThe company has deprioritized its oncology programs, which may impact its current focus and resources.

Cue Biopharma News

Cue Biopharma prices 35.7M shares at 28c in underwritten public offering

Cue Biopharma (CUE) announced the pricing of an underwritten public offering of 35,714,286 shares of its common stock...

7d ago

CUE

Cue Biopharma offers to sell common stock, no amount given

H.C. Wainwright & Co. is acting as sole book-running manager for the proposed offering. Newbridge Securities Corporation is...

8d ago

CUE

Cue Biopharma Announces $10 Million Public Equity Offering

Cue Biopharma ( ($CUE) ) has shared an update. On December 19, 2025, Cue Biopharma priced an underwritten...

7d ago

CUE

Cue Biopharma Releases Updated Corporate Presentation

Cue Biopharma ( ($CUE) ) has provided an update. On November 24, 2025, Cue Biopharma, Inc. made an...

1M ago

CUE

Cue Biopharma Announces CMO Departure

An announcement from Cue Biopharma ( ($CUE) ) is now available. On November 17, 2025, Cue Biopharma, Inc....

1M ago

CUE

Cue Biopharma, ImmunoScape enter exclusive in-licensing deal

ImmunoScape announced an exclusive in-licensing deal with Cue Biopharma (CUE) to lead the development of a distinct new...

1M ago

CUE

Cue Biopharma Reports Q3 2025 Financial Results

Cue Biopharma ( ($CUE) ) has released its Q3 earnings. Here is a breakdown of the information Cue...

1M ago

CUE

Cue Biopharma reports Q3 EPS (7c), consensus (9c)

Reports Q3 revenue $2.15M, consensus $2.29M. “During the third quarter of 2025 and early in the fourth quarter,...

1M ago

CUE

Cue Biopharma, ImmunoScape enter strategic collaboration, license agreement

Cue Biopharma (CUE) and ImmunoScape announced that they have entered into a collaboration and license agreement to advance...

2M ago

CUE

Cue Biopharma Partners with ImmunoScape for Cell Therapy

The latest announcement is out from Cue Biopharma ( ($CUE) ). On November 6, 2025, Cue Biopharma and...

2M ago

CUE

Cue Biopharma Appoints Usman Azam as New CEO

Cue Biopharma ( ($CUE) ) just unveiled an announcement. On September 26, 2025, Cue Biopharma announced the appointment...

3M ago

CUE

Cue Biopharma appoints Usman Azam as CEO

Cue Biopharma (CUE) announced that Usman “Oz” Azam, M.D., has been appointed President and CEO of Cue Biopharma,...

3M ago

CUE

Cue Biopharma initiated with a Buy at Lucid Capital

Lucid Capital analyst Dev Prasad initiated coverage of Cue Biopharma (CUE) with a Buy rating and $4 price...

4M ago

CUE

Cue Biopharma’s Q2 2025: Strategic Advances and Financial Highlights

Cue Biopharma ( ($CUE) ) has released its Q2 earnings. Here is a breakdown of the information Cue...

4M ago

CUE

CUE FAQ

What was Cue Biopharma Inc’s price range in the past 12 months?

Cue Biopharma Inc lowest stock price was $0.47 and its highest was $1.75 in the past 12 months.

What is Cue Biopharma Inc’s market cap?

Cue Biopharma Inc’s market cap is $21.99M.

When is Cue Biopharma Inc’s upcoming earnings report date?

Cue Biopharma Inc’s upcoming earnings report date is Mar 24, 2026 which is in 88 days.

How were Cue Biopharma Inc’s earnings last quarter?

Cue Biopharma Inc released its earnings results on Nov 12, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.093 by $0.023.

Is Cue Biopharma Inc overvalued?

According to Wall Street analysts Cue Biopharma Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cue Biopharma Inc pay dividends?

Cue Biopharma Inc does not currently pay dividends.

What is Cue Biopharma Inc’s EPS estimate?

Cue Biopharma Inc’s EPS estimate is -0.1.

How many shares outstanding does Cue Biopharma Inc have?

Cue Biopharma Inc has 91,237,740 shares outstanding.

What happened to Cue Biopharma Inc’s price movement after its last earnings report?

Cue Biopharma Inc reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.093. Following the earnings report the stock price went down -7.463%.

Which hedge fund is a major shareholder of Cue Biopharma Inc?

Currently, no hedge funds are holding shares in CUE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Cue Biopharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

-195.19%

Trailing 12-Months

Asset Growth

-3.83%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cue Biopharma Inc

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies aimed at harnessing the body's immune system to fight cancer and autoimmune diseases. The company operates primarily in the biopharmaceutical sector, specializing in its proprietary Cue Biologics platform, which enables the design of biologics to selectively modulate immune responses. Cue Biopharma's core products include immune modulators that target specific T cell populations, with several candidates currently in clinical trials for various indications.